[Anticonvulsive drug therapy. Historical and current aspects]

Area of Science:

• Pharmacology and Neurology
• Development of novel anticonvulsant medications

Context:

• Intractable focal epilepsies present a significant treatment challenge.
• Recent advancements have introduced new antiepileptic drugs (AEDs) to the therapeutic arsenal.
• Existing treatments often have limitations in efficacy and side effect profiles.

Purpose:

• To review the efficacy and side effect profiles of newly developed antiepileptic drugs.
• To compare the effectiveness of novel AEDs against established treatments for pharmacoresistant epilepsy.
• To explore the rational drug design principles guiding the development of new anticonvulsants.

Summary:

• New AEDs demonstrate comparable efficacy to older drugs, with approximately 20-30% of patients achieving >50% seizure reduction.
• Some novel AEDs show efficacy in generalized seizures and Lennox-Gastaut syndrome, often with improved side effect profiles.
• Mechanisms of action focus on modulating synaptic transmission, including enhancing GABAergic activity and interacting with NMDA receptors.

Impact:

• The development of new AEDs expands treatment options for patients with difficult-to-treat epilepsies.
• Understanding drug-specific side effects (e.g., vigabatrin, lamotrigine, felbamate) is crucial for patient management.
• The shift towards monotherapy trial designs may provide clearer efficacy data and facilitate comparisons with existing anticonvulsants.